Friday, May 01, 2015 8:28:08 PM
"..this is really just the beginning of an explosion of a large number of immunotherapeutics that are going to come along very..in rapid succession here in all having more and more activity here in this disease"
yes Bio, Dr. Antonia now advising "combinations..." with other biotechs and those combinations are not providing an optimal immune response without Bavituximab or anther PS Targeting agent (which Dr. Antonia must be adivising them since he has been with Peregrine since Dec 10, 2013)
-----------------------
Cellular Biomedicine Group Appoints Two New Members to Scientific Advisory Board
April 30, 2015
...
...
"Dr. Antonia is one of the foremost experts in the field of immuno-oncology and as a principal investigator of multiple high profile immuno-oncology clinical trials, including anti-PD-1 therapy for advanced lung cancer, has made significant strides with gene-modified tumor cell vaccine development. His research and experience in designing immunotherapy studies will no doubt advance our development of combination therapies for cancer, both in China and internationally. Professor Fan, an outstanding stem cell and neuro cell biologist, has made major contributions in the field of neuroscience and the epigenetic mechanisms underlying stem cell regulation, reprogramming, and human diseases. We look forward to Dr. Fan's research advances in the understanding of how stem cells self-renew and differentiate into specific cell types and leads to therapies for eye and neurodegenerative diseases."
"I look forward to working with Cellular Biomedicine Group in order to help bring to market safe and effective cancer therapeutics for such a large unmet medical need," said Dr. Antonia.
..
..
..
http://globenewswire.com/news-release/2015/04/30/730799/10131822/en/Cellular-Biomedicine-Group-Appoints-Two-New-Members-to-Scientific-Advisory-Board.html?print=1
...talking to myself on a friday night, all just a matter of time since how many stock options are locked up by now for PPHM ?? 2.5 - 3 Million shares possibly ??
I say yes and check out their PD-1 Mab in preclinical.... I think we just found another collaborator of the "dozens..." that Peregrine has been involved with. Nice to see there are other PD-1's out there (5th one down does not mention the Mab drug...or combination)
http://cellbiomedgroup.com/clinical-trials/
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
